In addition, BBV152/Covaxin generated a robust CD4+ T-cell response in most individuals (85%), which was stable for 6 months and included cells capable of recognizing spike and nucleoprotein with a frequency comparable to infection (160). This evidence concerns the gene CD4 and infection.